Hematologic Oncology | Specialty

Iomab-B Conditioning Therapy Leads to 100% Transplant, Engraftment Rate in Active Relapsed/Refractory AML

December 29th 2020

Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies

December 28th 2020

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Druker Details a Career of Determination, Patient Impact, and Family Success

December 24th 2020

In our exclusive interview, Brian Druker, MD, discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.

Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

December 23rd 2020

December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.

Dr. Lin on the Promise of Cilta-Cel and Ide-Cel in Myeloma

December 21st 2020

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

Dr. Jain on the Role of BTK Inhibitors in MCL

December 21st 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Gilteritinib/Azacitidine Fails to Significantly Improve OS in Newly Diagnosed FLT3+ AML

December 21st 2020

December 21, 2020 — The addition of gilteritinib to azacitidine failed to significantly improve overall survival vs azacitidine alone in patients with newly diagnosed FLT3-mutated acute myeloid leukemia who were not eligible for intensive induction chemotherapy, failing to meet the primary end point of the LACEWING trial.

BLA Initiated for JZP-458 in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

December 21st 2020

December 21, 2020 - The submission of a biologics license application to the FDA has been initiated for JZP-458 for use as a component of a multiagent chemotherapy regimen in the treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.

FDA Approves Ponatinib for Resistant or Intolerant Chronic-Phase CML

December 18th 2020

December 18, 2020 - The FDA has approved ponatinib for the treatment of patients with chronic-phase chronic myeloid leukemia that is resistant or intolerant to at least 2 prior kinase inhibitors.

The Rationale for Targeting BCMA in Multiple Myeloma

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

December 18th 2020

FDA Approves Rituximab Biosimilar for NHL, CLL, GPA, and MPA

December 17th 2020

December 17, 2020 - The FDA has approved rituximab-arrx, a biosimilar to rituximab, for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigm

December 17th 2020

Jorge E. Cortes, MD, shares advice for navigating among first- and second-generation TKIs in the frontline treatment of patients with chronic myeloid leukemia.

Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CML

December 17th 2020

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

December 15th 2020

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Dr. Sweet on Treatment Selection With TKIs in CML

December 15th 2020

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

FDA Grants Fast Track Designation to Devimistat for AML

December 15th 2020

December 15, 2020 - The FDA has granted a fast track designation to devimistat for the treatment of patients with acute myeloid leukemia.

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

December 15th 2020

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

December 15th 2020

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. DeAngelo on the Mechanism of Action of Pevonedistat in MDS

December 15th 2020

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.